IMMUNOCORE HLDGS ADS/1 Cash Flow-to-Debt Ratio
IMMUNOCORE HLDGS ADS/1 cash flow-to-debt ratio. IMMUNOCORE HLDGS ADS/1 (6YG) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2026, meaning its operating cash flow of €15.93 Million could theoretically repay 0% of its total liabilities (€699.62 Million) in one year. Check cash flow quality index of IMMUNOCORE HLDGS ADS/1 to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of IMMUNOCORE HLDGS ADS/1 (2022–2025)
Cash flow-to-debt ratio of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. Historical debt coverage capacity for IMMUNOCORE HLDGS ADS/1 across 4 annual periods. Check 6YG total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
IMMUNOCORE HLDGS ADS/1 Cash Flow-to-Debt Ratio by Year (2022–2025)
IMMUNOCORE HLDGS ADS/1 cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for IMMUNOCORE HLDGS ADS/1. For the full cash flow conversion analysis, see IMMUNOCORE HLDGS ADS/1 operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | €-10.71 Million | €686.24 Million | ▼ -138.9% |
| 2024 | 0.04x | €26.06 Million | €648.79 Million | ▲ +211.7% |
| 2023 | 0.01x | €2.94 Million | €228.16 Million | ▲ +104.9% |
| 2022 | -0.26x | €-49.21 Million | €187.86 Million | — |